AngioDynamics Launches MORPHEUS CT PICC INSERTION KIT Nationwide
AngioDynamics Launches MORPHEUS CT PICC INSERTION KIT Nationwide
May 9, 2006 at 12:00 AM EDT
QUEENSBURY, N.Y.--(BUSINESS WIRE)--May 9, 2006--AngioDynamics, Inc. (NASDAQ:ANGO) today announced the nationwide launch of the MORPHEUS® CT PICC INSERTION KIT. Use of the INSERTION KIT allows the Company's proprietary peripherally inserted central catheter (PICC) to be inserted at a patient's bedside, instead of in the interventional radiology suite at the hospital, which is the current practice. The INSERTION KIT, which has been specifically designed for interventional radiologists, nurse practitioners, physician assistants and radiology technicians who perform the placement of PICCs, is now available for immediate distribution throughout the United States.
"The MORPHEUS CT PICC INSERTION KIT reflects our continued dedication and commitment to expanding our product offerings to meet the needs of our customers and their patients, and we are very excited that this kit is now available for sale across the Unites States," commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics.
"Our new product offering includes everything needed to safely insert the MORPHEUS CT PICC at the patient's bedside, thus reducing physician time and improving patient comfort. Complementing our current MORPHEUS CT PICC basic and full kits, the INSERTION KIT provides customers a choice of where to perform the procedure," Mr. Hobbs added.
The MORPHEUS CT PICC is used for short and long-term peripheral access to the central venous system for intravenous therapy and power injections of contrast media. It features the dual durometer catheter shaft made of Durathane™, a biocompatible and durable material that offers increased stiffness for ease of placement while also providing patient comfort. The use of Durathane also helps simplify site care since the material can be cleaned with either iodine or alcohol.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products, dialysis products, vascular access products, PTA products, oncology products, thrombolytic products and venous products.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, results of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc.
Michelle Mechaley, 800-772-6446 x341
mmechaley@angiodynamics.com
http://www.angiodynamics.com/
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
SOURCE: AngioDynamics, Inc.
"The MORPHEUS CT PICC INSERTION KIT reflects our continued dedication and commitment to expanding our product offerings to meet the needs of our customers and their patients, and we are very excited that this kit is now available for sale across the Unites States," commented Eamonn P. Hobbs, president and chief executive officer of AngioDynamics.
"Our new product offering includes everything needed to safely insert the MORPHEUS CT PICC at the patient's bedside, thus reducing physician time and improving patient comfort. Complementing our current MORPHEUS CT PICC basic and full kits, the INSERTION KIT provides customers a choice of where to perform the procedure," Mr. Hobbs added.
The MORPHEUS CT PICC is used for short and long-term peripheral access to the central venous system for intravenous therapy and power injections of contrast media. It features the dual durometer catheter shaft made of Durathane™, a biocompatible and durable material that offers increased stiffness for ease of placement while also providing patient comfort. The use of Durathane also helps simplify site care since the material can be cleaned with either iodine or alcohol.
About AngioDynamics
AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products, dialysis products, vascular access products, PTA products, oncology products, thrombolytic products and venous products.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, results of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 28, 2005, may affect the actual results achieved by the Company.
CONTACT: AngioDynamics, Inc.
Michelle Mechaley, 800-772-6446 x341
mmechaley@angiodynamics.com
http://www.angiodynamics.com/
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com
SOURCE: AngioDynamics, Inc.